Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

J Thromb Haemost. 2005 Apr;3(4):692-4.

2.

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.

Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

J Thromb Haemost. 2010 Jan;8(1):202-4. doi: 10.1111/j.1538-7836.2009.03678.x. Epub 2009 Oct 30. Review.

3.

[Hemostasis-altering drugs and regional anesthetic techniques: safety guidelines].

Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, Gómez Luque A, Hidalgo Martínez F, Torres Morera LM.

Rev Esp Anestesiol Reanim. 2004 Mar;51(3):137-42. Spanish.

PMID:
15200185
4.

Clinical pharmacology of antithrombotic drugs in coronary artery disease.

Fauler J.

Ther Adv Cardiovasc Dis. 2009 Dec;3(6):465-78. doi: 10.1177/1753944709346517. Epub 2009 Sep 2. Review.

PMID:
19726525
5.

[Endoscopy in patients receiving anticoagulation or antiplatelet therapy].

Kjeldsen J, Pless T, Meisner S, Bytzer P.

Ugeskr Laeger. 2009 Apr 20;171(17):1384-6. Danish.

PMID:
19413934
6.

Haemostasis, anticoagulants and fibrinolysis.

Casey G.

Nurs Stand. 2003 Oct 29-Nov 4;18(7):45-51; quiz 53, 55. Review.

PMID:
14639979
7.

Bleeding risks of antithrombotic therapy.

Fitzmaurice DA, Blann AD, Lip GY.

BMJ. 2002 Oct 12;325(7368):828-31. Review. No abstract available.

8.

[The antithrombotic-treated patient].

Nielsen JD, Rasmussen HM, Husted SE.

Ugeskr Laeger. 2006 Dec 4;168(49):4296-9. Danish.

PMID:
17164056
9.

Discrepancies in identification of major bleeding events in patients taking warfarin.

Seto AC, Kenyon K, Wittkowsky AK.

Pharmacotherapy. 2008 Sep;28(9):1098-103. doi: 10.1592/phco.28.9.1098.

PMID:
18752380
10.

[Locoregional spinal anesthesia and hemostasis: fewer problems, more solutions].

Samama CM.

Rev Esp Anestesiol Reanim. 2005 Aug-Sep;52(7):382. Spanish. No abstract available.

PMID:
16200916
11.

Difference in interpretation of computed tomography pulmonary angiography diagnosis of subsegmental thrombosis in patients with suspected pulmonary embolism.

Pena E, Kimpton M, Dennie C, Peterson R, LE Gal G, Carrier M.

J Thromb Haemost. 2012 Mar;10(3):496-8. doi: 10.1111/j.1538-7836.2011.04612.x. No abstract available.

12.

A risk score to predict bleeding in patients with acute coronary syndromes.

Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.

J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66. doi: 10.1016/j.jacc.2009.09.076.

13.

New antithrombotic drugs.

Gross PL, Weitz JI.

Clin Pharmacol Ther. 2009 Aug;86(2):139-46. doi: 10.1038/clpt.2009.98. Epub 2009 Jun 24. Review.

PMID:
19553932
15.

[Antithrombotic agents].

Yamazaki M, Uchiyama S.

Nihon Rinsho. 2012 Aug;70 Suppl 6:231-8. Japanese. No abstract available.

PMID:
23156514
16.

Abnormal coagulation in the postoperative period contributing to excessive bleeding.

McKenna R.

Med Clin North Am. 2001 Sep;85(5):1277-310, viii. Review.

PMID:
11565500
17.

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.

van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, Remick SC.

Curr Opin Hematol. 2007 Sep;14(5):468-80. Review.

PMID:
17934353
18.

Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.

Kleiman NS.

Am Heart J. 1999 Oct;138(4 Pt 2):263-75. Review.

PMID:
10502232
19.

Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.

Greaves M; Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.

Thromb Haemost. 2002 Jan;87(1):163-4. No abstract available.

PMID:
11848446
20.

[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].

Prisco D.

Haematologica. 2001 Sep;86(9 Suppl):12-3. Italian. No abstract available.

PMID:
11759618

Supplemental Content

Support Center